Glaxo SmithKline Co.'s net profits for 2014 declined by 16.5%, down to EGP 64.1 million from EGP 76.8 million in 2013.

Meanwhile, the company reported net profits of EGP 28.4 million in the first nine months of 2014, compared with EGP 37.3 million for the same period of the previous year.
 
Glaxo SmithKline is capitalised at EGP 835.1 million, distributed at 83.5 million shares at EGP 10 each.